Related Experiment Video
Updated: May 5, 2026

Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
Published on: October 15, 2019
The microbiota-gut-brain axis in mild cognitive impairment and Alzheimer's disease: a scoping review of human studies
Alison Warren1, Zan Wynia2, Patrick G Corr1
1The Frame-Corr Laboratory, Department of Clinical Research and Leadership, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
Abstract:
Alzheimer's disease (AD) is projected to become the highest-burden neurological disorder globally. Mounting evidence implicates the gut microbiome in AD pathogenesis. This scoping review of gut microbiomes in mild cognitive impairment (MCI) and AD included dietary and probiotic interventions. We included original research and systematic reviews/meta-analyses. Animal and non-English studies were excluded. We searched PubMed, Scopus, and Cochrane Library through February 2023. Using Arksey and O'Malley's framework and the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)-Extension for Scoping Reviews (ScR) checklist, we screened 4751 articles, with 58 meeting predefined inclusion criteria. Our results demonstrated that gut dysbiosis was frequently reported in MCI and AD, including increased Pseudomonadota and Actinomycetota in AD and reduced diversity in some cases. Probiotic and dietary interventions showed promise in modulating cognition and microbiota, inconsistently. Emerging evidence links dysbiosis to cognitive decline; however, methodological heterogeneity and limited follow-up impede causal inference. Research should prioritize standardized protocols, functional microbiome analysis, and longitudinal human studies to clarify therapeutic potential. HIGHLIGHTS: Gut dysbiosis is a common feature of MCI and AD, with phylum-level microbial shifts frequently observed. Pseudomonadota and Actinomycetota are enriched in AD across multiple human studies. Beneficial genera like Faecalibacterium and Roseburia are consistently reduced in MCI and AD in a small number of studies. Probiotic and dietary interventions are promising to modulate the microbiota-cognition axis. More longitudinal human studies are needed to assess causal microbiome relationships.
Insights
Gut dysbiosis, an imbalance in gut bacteria, is common in Alzheimer's disease (AD) and mild cognitive impairment (MCI). Interventions targeting the gut microbiome show potential for cognitive health.
Area of Science:
- Microbiome Research
- Neurological Disorders
- Gastroenterology
Background:
- Alzheimer's disease (AD) poses a significant global health burden.
- Growing evidence links the gut microbiome to AD pathogenesis.
- Mild cognitive impairment (MCI) is an early stage often preceding AD.
Purpose of the Study:
- To conduct a scoping review of gut microbiome research in MCI and AD.
- To examine the impact of dietary and probiotic interventions on the gut microbiome and cognition.
- To identify research gaps and future directions in the field.
Main Methods:
- Searched PubMed, Scopus, and Cochrane Library up to February 2023.
- Included original research and systematic reviews/meta-analyses (human studies only).
- Screened 4751 articles, with 58 meeting inclusion criteria using PRISMA-ScR guidelines.
Main Results:
- Gut dysbiosis frequently observed in MCI and AD.
- Increased abundance of Pseudomonadota and Actinomycetota in AD.
- Reduced microbial diversity noted in some MCI/AD cases.
- Probiotic and dietary interventions showed inconsistent but promising effects on cognition and microbiota.
Conclusions:
- Gut dysbiosis is a prevalent feature in MCI and AD.
- Specific microbial shifts are associated with cognitive decline.
- Interventions modulating the gut microbiota-cognition axis warrant further investigation.
- Standardized protocols and longitudinal human studies are crucial for causal inference and therapeutic development.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Introduction to the Human Microbiota
Development of Human Microbiota
Functions of the Gut Microbiota
Gut-Brain Axis
Alzheimer Disease ll: Pathophysiology

